Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

Activating mutations in the BRAF gene are among the most prevalent kinase mutations in
human cancer. BRAF mutations are most frequent in patients with melanoma where they …

Checkpoint blockade immunotherapy is the current standard treatment strategy for
inoperable stage IV BRAF wild-type (WT) melanoma [1, 2]. Targeted treatment with BRAF …

Patients with melanoma with activating BRAF mutations (BRAF V600E/K) initially respond to
combination therapy of BRAF and MEK inhibitors. However, their clinical efficacy is limited …

The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway
involved in the regulation of cellular proliferation and the survival of tumor cells. Several …

Combination therapy of melanoma using kinase inhibitors : Current Opinion in Oncology
Combination therapy of melanoma using kinase inhibitors : Current Opinion in Oncology Log …

Overview: Anticancer drug resistance remains a crucial impediment to the care of many
patients with cancer. Although the exact mechanisms of resistance may differ for each …

Selective inhibition of the mitogen activated protein kinase (MAPK) pathway with either
BRAF or MEK inhibition has emerged as the key component for the treatment of BRAF …

Recent clinical studies have shown that combination therapy of BRAF and MEK inhibition
provides more survival benefit than BRAF inhibition monotherapy. However, the adverse …

The discovery of BRAF mutations in melanoma has not yet translated into clinical success,
suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the …